• Trice Medical

  Led · Series C · Jan 2019

  Trice Medical develops a portable, tablet-based imaging platform that combines a disposable needle camera (mi-eye™) with a high-quality ultrasound transducer (mi-ultra™) for orthopedic procedures. The company’s products are intended to enable procedures outside of traditional imaging suites. Since 2019, Trice has acquired Seg-WAY™ Orthopedics and Tenex Health, expanding its capabilities in minimally invasive ultrasonic technology for chronic pain treatment. The company is led by CEO and President Mark Foster. Trice announced a Series D financing whose amount was not disclosed and entered a strategic arrangement with Bioventus as part of the transaction. As described in the articles, Trice and Bioventus will pursue co-development to explore integration of their technologies to accelerate adoption of both companies’ offerings. Trice Medical, based in Malvern, Pa., makes integrated, camera-enabled and ultrasound platforms for minimally invasive orthopedic diagnostics, including the mi-eye 2 disposable arthroscopy camera and the mi-ultra 15 MHz handheld ultrasound transducer. The company’s Dynamic Imaging Platform combines the mi-eye technology with the mi-ultra on a single portable platform. Trice says its mission is to provide more immediate and definite patient care, reduce false reads from indirect modalities, and significantly lower healthcare costs. The company plans to expand worldwide commercialization of mi-eye 2 and mi-ultra and to accelerate development of its minimally invasive product portfolio. Management described 2019 as a transformational year, with plans to expand sales globally, launch several new products and announce large multinational partnerships. Trice Medical, based in King of Prussia, Pa., has developed the mi-eye2, a fully integrated camera-enabled handheld diagnostic scope that lets physicians diagnose joint injuries from the office. The mi-eye2 uses a disposable needle embedded with a wide-angle camera lens and improved vision quality to provide a non-invasive, more complete diagnosis. The device is currently being used by nearly 100 physician practices across 25 states. The company intends to use recent funding to accelerate and expand U.S. market penetration, support R&D, and grow sales and marketing. Trice Medical also plans to pursue key international regulatory approvals. Jeffrey O’Donnell, Sr. serves as President and CEO. The company has raised $40.9M to date. Trice Medical develops micro-invasive diagnostic tools for in-office procedures. Its core product, the mi-eye, is a fully disposable, single-use visualization device that uses a standard 14-gauge needle with an integrated camera and light to perform diagnostic arthroscopy during the initial consultation. An LCD tablet running Android OS attaches via a data cable to display images from the mi-eye needle. The company closed an $18.1M Series B financing led by HealthQuest Capital. Following the round, Trice appointed Craig Carra as its newly created Chief Financial Officer. Carra is a medical device and services veteran with roughly 20 years of experience and prior roles at Coopers & Lybrand, Surgical Laser Technologies, PhotoMedex and Ella Health. Trice Medical's core product, mi-eye, is a fully disposable, single‑use visualization device that integrates a camera and light source into a standard 14‑gauge needle to perform diagnostic arthroscopy in the physician's office. The device connects via a data cable to a separate Android‑based LCD tablet and is delivered sterile and ready for immediate use. Trice positions mi-eye to provide faster, more definitive, and less expensive diagnoses by eliminating false reads from indirect modalities such as MRI. The company received FDA 510(k) clearance for mi-eye, which it described as a key regulatory milestone. Trice plans to apply for CE Mark in Europe and seek approvals in other countries, and intends a limited marketing launch beginning in Q4 2014 while building inventory and developing marketing and educational programs. Financially, the company received the balance of cash related to an $11.6M Series B financing led by Safeguard Scientifics.

• Calysta

  Participated · Series D · May 2017

  Calysta develops and commercializes FeedKind®, a sustainable, traceable single‑cell protein alternative feed ingredient for fish, livestock and pet nutrition. The company’s technology uses a proprietary, commercially validated gas fermentation process with naturally occurring, non‑GM microbes that use methane as an energy source. Calysta intends to use the new funding to support global scale‑up of FeedKind production and to scope and pre‑develop a production site outside Asia. It is currently working toward completion of a commercial FeedKind production facility in China through Calysseo, its 50/50 joint venture with Adisseo, which is set to come online late 2022. The company also operates an R&D facility in the UK. The business is led by Thomas Huot, Ph.D., and its COO. Calysta develops and commercializes FeedKind, a sustainable single-cell protein feed ingredient produced through a patented gas fermentation process using naturally occurring, non-GM microbes that consume methane. The product requires no arable land and very little water, and does not compete with the human food chain. Calysta has positioned FeedKind initially for aquaculture and has completed extensive customer trials demonstrating its safety and nutritional efficacy. FeedKind is already being produced at Calysta’s Market Introduction Facility (MIF) in Teesside, England to support market development with animal nutrition companies. The company is pursuing a worldwide rollout and plans to deploy multiple production plants to scale supply. Recent capital and a strategic partnership are intended to accelerate production expansion and commercial deployment. Calysta develops and commercializes FeedKind® protein, a family of sustainable, traceable nutritional ingredients for fish, livestock and pets. The company intends to use the majority of its Series D proceeds to advance commercial-scale manufacturing of FeedKind. Calysta expects FeedKind to enter commercial production in 2019 and is pursuing large-scale gas fermentation capacity. In November 2016 Calysta and Cargill, with several third-party investors, announced plans for a gas fermentation facility in Memphis, TN to produce FeedKind. That Memphis facility is expected to come online in 2019, producing up to 20,000 metric tons per year initially and expanding to up to 200,000 metric tons per year at full capacity. Calysta also operates a Market Introduction Facility in the United Kingdom supplying sample quantities of FeedKind for customers and is working with strategic investors on marketing, distribution and production expansion. Calysta develops sustainable proteins and industrial materials using a proprietary gas fermentation platform. Its Calysta Nutrition unit commercializes FeedKind™ protein, a family of environmentally friendly nutritional feed additives for fish and livestock, while Calysta Energy focuses on high-value industrial materials. The company completed a $30 million Series C financing to advance new product development, commercial manufacturing and continued platform advances. Calysta plans to scale FeedKind™ production and commercial introduction, including collaboration with Cargill on North American manufacturing and global marketing. In January 2016 the company announced conditional receipt of a UK grant to develop a Market Introduction Facility in northern England as its first research and market introduction facility for FeedKind™. Calysta is an innovator in sustainable industrial products for food and energy security, based in Menlo Park, CA. The company operates two business units: Calysta Nutrition, which develops and commercializes fish and livestock nutritional products, and Calysta Energy, which is developing high-value materials for industrial and consumer products. Its flagship offering is Microbial Protein™ Feed aimed at making aquaculture feed more sustainable and efficient. Calysta intends to advance development and market introduction of its high-value nutritional products as well as traditional chemical products. The company completed a $10 million Series B to support those development and commercialization efforts. No operating metrics (revenue/users) are disclosed in the article.

• Aperia Technologies

  Led · Equity · Nov 2016

  Aperia Technologies develops the Halo Tire Management suite, combining self-powered tire pressure automation hardware with a machine-learning analytics platform to deliver operational, safety, and sustainability improvements for commercial fleets. Its technology improves fuel economy for diesel vehicles, extends range for electric vehicles, and supports broad fleet applications across vehicle classes. Aperia reports nearly one million tires under management in North America and adoption by nearly 15 percent of leading heavy-duty fleets specifying its technology on new trucks. The company offers products including Halo Connect, Halo Trailer Connect, and Halo Tire Inflator to optimize fleet tire management practices and reduce downtime, maintenance costs, and tire expenditures. Aperia plans to use new capital to accelerate its product development roadmap, expand into new markets, and pilot new customer delivery models to scale globally. Aperia Technologies develops tire management hardware and analytics aimed at improving safety, efficiency, and environmental impact for commercial fleets. Its flagship Halo Tire Inflator and the recently introduced Halo Connect analytics platform use proprietary algorithms trained over more than half a decade and a billion miles to detect tire health issues early. The company says fleets using its products can substantially reduce unplanned tire-related downtime, tire expenditures, and CO2 emissions from under-inflation. Aperia has adopted partnerships with tire manufacturers and prominent U.S. commercial fleets to commercialize its solutions. The firm intends to scale Halo Connect, expand into new global markets, and support progression toward connected and autonomous vehicle applications. The announcement was released from Burlingame, Calif. Aperia Technologies develops the Halo Tire Inflator, a self-powered, bolt-on automatic tire inflation system that uses wheel rotation to generate pressure and maintain optimal tire inflation without a central air compressor. The company has seen record growth with Halo installed on more than 170 fleets and thousands of tractors and trailers. To meet demand it operates a dedicated U.S. manufacturing facility that expanded the production footprint five-fold and will boost capacity to 250,000 units for 2017. Aperia plans to use new funding to invest in sales and marketing infrastructure and to expand customer support operations across industry segments. The company positions itself to benefit from an EPA/NHTSA Phase 2 fuel-economy rule that designates automatic tire inflation systems as integral to improving fuel economy, which the company says should accelerate adoption. Aperia was founded out of Stanford University in 2010 and emphasizes making transportation more efficient, safer, and better for the environment.

No current team members are available.